CombiGene´s lead project CG01 has received funding from the European Union´s Horizon 2020 research and innovation programme

Market for epilepsy project


Epilepsy is a condition that affects one percent of the human population worldwide, making it one of the most common neurological diseases. Epilepsy may be caused by a brain injury or by a genetic tendency. In most cases, however, the cause is not known. The cause normally has no bearing on the choice of treatment.

Costs for epilepsy in the USA exceed USD 12.5 billion.
In the USA alone it is estimated that society’s cost for epilepsy exceeds USD 12.5 billion per year. There are several antiepileptic drugs, but about a third of patients cannot be adequately helped by these drugs or suffer serious side effects. For some patients, the condition can be alleviated with the help of resective surgery, a procedure whereby the part of the brain that causes the seizures is surgically removed; however, for the majority of drug-resistant patients, a safe and effective treatment is not yet available.

Target group
CombiGene’s therapy is intended for those who cannot currently be helped.

This group may be as much as 0.2-0.3 percent of the population, which corresponds to about 2.5 million people in the USA and Europe alone. Within this group of drug-resistant patients is a smaller group of patients who suffer from focal onset epileptic seizures and for whom resective surgery may be appropriate. These are the patients for whom CombiGene’s method is primarily intended.

1. Bell GS and Sander JW (2001). The epidemiology of epilepsy:
The size of the problem. Seizure, 10:306-314.